Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Getting a neuroendocrine tumor (NET) before age 50 comes with a notable finding: a significantly lower chance of developing a second cancer. A large SEER database study found that early-onset NET patients had a 4.97% rate of subsequent primary cancers, versus 8.06% in older patients. Researchers say the findings don't warrant changes to standard cancer screening guidelines, but do highlight the need for personalized survivorship care.
Getting diagnosed with a neuroendocrine tumor (NET) before age 50 is associated with a meaningfully lower risk of developing a second primary cancer (SPC), according to a new cohort study published in JAMA Network Open. Researchers analyzed data from over 95,000 NET patients in the SEER database (2000–2021) and found that early-onset patients had a substantially reduced hazard for SPC compared to those diagnosed at 50 or older — though the protective effect diminished over time.
The study also revealed important nuances within the early-onset group. Male sex and appendiceal NETs were linked to lower SPC risk, while pancreatic, gastric, and small-intestine NETs were associated with higher risk — underscoring that early-onset NET is far from a one-size-fits-all diagnosis.
By the Numbers:
Why it matters: These findings don't call for changes to existing cancer screening protocols, but they do signal that survivorship care for NET patients should be tailored — factoring in age of onset, tumor site, and demographics — rather than applying a blanket approach.